|Bid||7.40 x 1800|
|Ask||7.78 x 800|
|Day's Range||7.15 - 9.00|
|52 Week Range||3.12 - 19.25|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q1 2020 Cyclacel Pharmaceuticals Inc Earnings Call
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
\-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1,.